oral tumor
Recently Published Documents

Information on neoplasms in animals has increased over time, and these studies have helped in the management of reptiles that present tumors. There are similar incidences of neoplasms between homeothermic and ectothermic animals. Furthermore, there are usually more than one type of tumor present. The treatment of wild animals afflicted with cancer usually happens late, contributing to their low life expectancy. Thus, the present work aimed to describe an infrequent case of oral tumor in Boa constrictor. The tumor was observed in an adult female animal, raised in an exhibition area of the Zoo and Botanical Park of the Emílio Goeldi Museum, located in Belém, State of Pará, Brazil. Macroscopically, the mass presented morphologically with an irregular, multilobulated surface, color that varied from white to grey, hemorrhagic areas and its extension was 3.9 x 2.3 cm. The neoplasm was surgically removed, and the histopathological evaluation revealed an adenocarcinoma, with a papillary-like development pattern and a moderate degree of differentiation. The animal died three months after diagnosis due to starvation. The necropsy showed that there was tumor recrudescence and no metastases. Given the impossibility of surgical removal with a greater margin of safety, and adjuvant therapies, this condition favoured the resurgence of the neoplasm. This compromised the animal’s ability to feed and consequently lead to death. Malignant neoplasms in reptiles may have an unfavourable clinical evolution for the maintenance of life, requiring specific therapeutic care such as chemotherapy. Scientific contributions on tumors in these animals are essential for the medical treatment of wild animals, and the conservation of wild species.

Abstract Background Human Papillomavirus type 16 (HPV16) has been associated with a subset of head and neck cancers. Two HPV encoded oncogenic proteins, E6 and E7, are important for the malignant progression of HPV-associated cancers. A spontaneous HPV16 E6/E7-expressing oral tumor model in human HLA-A2 (AAD) transgenic mice will be important for the development of therapeutic HPV vaccines for the control of HPV-associated head and neck cancers. Methods In the current studies, we characterized the HLA-A2 restricted HPV16 E7-specific CD8 + T cell mediated immune responses in the HLA-A2 (AAD) transgenic mice using a therapeutic naked DNA vaccine encoding calreticulin (CRT) linked to a mutated E7(N53S). We also employed oncogenic DNA plasmids that encoded HPV16E6/E7/Luc, NRasG12V, and sleeping beauty transposase for the transfection into the submucosal of oral cavity of the transgenic mice with electroporation to create a spontaneous oral tumor. Furthermore, we characterized the therapeutic antitumor effects of CRT/E7(N53S) DNA vaccine using the spontaneous HPV16 E6/E7-expressing oral tumor model in HLA-A2 (AAD) transgenic mice. Results We found that CRT/E7(N53S) DNA vaccine primarily generated human HPV16 E7 peptide (aa11-20) specific CD8 + T cells, as compared to the wild-type CRT/E7 vaccine, which primarily generated murine H-2Db restricted E7 peptide (aa49-57) specific CD8 + T cell responses. We also observed transfection of the oncogenic DNA plasmids with electroporation generated spontaneous oral tumor in all of the injected mice. Additionally, treatment with CRT/E7(N53S) DNA vaccine intramuscularly followed by electroporation resulted in significant antitumor effects against the spontaneous HPV16 E6/E7-expressing oral tumors in HLA-A2 (AAD) transgenic mice. Conclusions Taken together, the data indicated that the combination of HPV16 E6/E7-expressing DNA, NRasG12V DNA and DNA encoding sleeping beauty transposase is able to generate spontaneous oral tumor in HLA-A2 (AAD) transgenic mice, which can be successfully controlled by treatment with CRT/E7(N53S) DNA vaccine. The translational potential of our studies are discussed.

Abstract Background Oral metastasis by hepatocellular carcinoma (OMHCC) is extremely rare, and the prognosis had been reported quite poor due to simultaneous multiple organ metastases. In this study, we report clinical features and survival of 10 new cases of OMHCC and suggest the criteria for palliative surgery. Methods A retrospective clinical study including 10 new cases of oral OMHCC between 2006 and 2016 was performed. Clinical features and survival analysis were examined. The recorded variables were age, sex, site of oral metastases, size of oral tumor (largest diameter), and survival after oral histopathologic diagnosis. Results There was male (n=8) predilection of OMHCC. The mean survival time was 16.9 months. Patient age ranged from 40 to 71 years (mean 56.5). Eight mandibular and two maxillary lesions were found. One patient showed simultaneously the maxilla and the oral tongue involvement. The most often encountered symptoms were swelling (80%) followed by pain (60%), numbness (60%), bleeding (10%), and tooth mobility (10%). Four patients underwent operation due to spontaneous bleeding and swelling of the cancer. Overall (from onset of hepatocellular carcinoma) and truncated survival (from onset of OMHCC) were 71.9 and 13.1 months respectively. Conclusion The prognosis of OMHCC was quite poor. Oral and jaw bone examination should be included in patients with multiple metastasis of HCC. Palliative surgery might be performed in patients who reported spontaneous bleeding, severe pain, and oral dysphasia due to tumor enlargement.

Metal artifacts are considered a major challenge in computed tomography (CT) as these adversely affect the diagnosis and treatment of patients. Several approaches have been developed to address this problem. The present study explored the clinical potential of a novel photon-counting detector (PCD) CT system in reducing metal artifacts in head CT scans. In particular, we studied the recovery of an oral tumor region located under metal artifacts after correction. Three energy thresholds were used to group data into three bins (bin 1: low-energy, bin 2: middle-energy, and bin 3: high-energy) in the prototype PCD CT system. Three types of physical phantoms were scanned on the prototype PCD CT system. First, we assessed the accuracy of iodine quantification using iodine phantoms at varying concentrations. Second, we evaluated the performance of material decomposition (MD) and virtual monochromatic images (VMIs) using a multi-energy CT phantom. Third, we designed an ATOM phantom with metal insertions to verify the effect of the proposed metal artifact reduction. In particular, we placed an insertion-mimicking an iodine-enhanced oral tumor in the beam path of metallic objects. Normalized metal artifact reduction (NMAR) was performed for each energy bin image, followed by an image-based MD and VMI reconstruction. Image quality was analyzed quantitatively by contrast-to-noise ratio (CNR) measurements. The results of iodine quantification showed a good match between the true and measured iodine concentrations. Furthermore, as expected, the contrast between iodine and the surrounding material was higher in bin 1 image than in bin 3 image. On the other hand, the bin 3 image of the ATOM phantom showed fewer metal artifacts than the bin 1 image because of the higher photon energy. The result of quantitative assessment demonstrated that the 40-keV VMI (CNR: 20.6 ± 1.2) with NMAR and MD remarkably increased the contrast of the iodine-enhanced region compared with that of the conventional images (CNR: 10.4 ± 0.5) having 30 to 140 keV energy levels. The PCD-based multi-energy CT imaging has immense potential to maximize the contrast of the target tissue and reduce metal artifacts simultaneously. We believe that it would open the door to novel applications for the diagnosis and treatment of several diseases.

Introduction: Previous studies have demonstrated that glycosaminoglycan hyaluronic acid (HA) is capable of mediating oral tumor growth. Some clinical evidence has suggested reduced HA expression predicts poor cancer prognosis and that HA-chemotherapy conjugates may function synergistically to inhibit oral tumor growth. Other studies have found conflicting results that suggest enhanced CD44-HA-mediated growth and proliferation. Due to the lack of clarity regarding HA function, the primary goal of this study was to investigate the effects of HA using well-characterized oral cancer cell lines. Methods: Using several commercially available oral squamous cell carcinoma lines (and a normal non-cancerous control), 96-well growth and viability assays were conducted using HA (alone and in combination with chemotherapeutic agents paclitaxel and PD98059). Results: Different results were observed in each of the cell lines evaluated. HA induced small, non-significant changes in cellular viability among each of the cell lines within a narrow range (1–8%), p = 0.207. However, HA induced differing effects on growth, with minimal, non-significant changes among some cell lines, such as SCC4 (+1.7%), CCL-30 (−2.8%), and SCC15 (−2.5%), p = 0.211 and more robust inhibition among other cell lines, SCC9 (−24.4%), SCC25 (−36.6%), and CAL27 (−47.8%), p = 0.0001. Differing effects were also observed with growth and viability under concomitant administration of HA with PD98059 or paclitaxel. Further analysis of these data revealed strong inverse (Pearson’s) correlations between initial baseline growth rate and responsiveness to HA administration, ranging from R = −0.27 to R = −0.883. Conclusion: The results of this study revealed differing responses to HA, which may be inversely correlated with intrinsic characteristics, such as the baseline growth rate. This may suggest that the more rapidly growing cell lines are more responsive to combination therapy with hyaluronic acid; an important finding that may provide insights into the mechanisms responsible for these observations.